Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy

A step-by-step guide to exposure and efficiency

Stephen Williams, Yasar Bozkurt, Mary Achim, Grace Achim, John W. Davis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective To describe a novel, step-by-step approach to robot-assisted extended pelvic lymph node dissection (ePLND) at the time of robot-assisted radical prostatectomy (RARP) for intermediate-high risk prostate cancer. Patient and Methods The sequence of ePLND is at the beginning of the operation to take advantage of greater visibility of the deeper hypogastric planes. The urachus is left intact for an exposure/retraction point. The anatomy is described in terms of lymph nodes (LNs) that are easily retrieved vs those that require additional manipulation of the anatomy, and a determined surgeon. A representative cohort of 167 RARPs was queried for representative metrics that distinguish the ePLND: 146 primary cases and 21 with neoadjuvant systemic therapy. Results The median (interquartile range, IQR) LN yield was 22 (16-28) for primary surgeries and 21 (16-23) for neoadjuvant cases. The percentage of cases with positive LNs (pN1) was 16.4% for primary and 29% for neoadjuvant. The hypogastric LNs were involved in 75% of pN1 primary cases and uniquely positive in 33%. Each side of ePLND took the attending surgeon a median (IQR) of 16 (13-20) min and trainees 25 (24-38) min. Conclusions Robot-assisted ePLND before RARP provides an anatomical approach to surgical extirpation mimicking the open approach. We think this sequence offers efficiency and efficacy advantages in high-risk and select intermediate-risk patients with prostate cancer undergoing RARP.

Original languageEnglish (US)
Pages (from-to)192-198
Number of pages7
JournalBJU International
Volume117
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Prostatectomy
Lymph Node Excision
Lymph Nodes
Prostatic Neoplasms
Anatomy
Urachus
Neoadjuvant Therapy
Surgeons

Keywords

  • high risk
  • lymphadenectomy
  • prostate cancer
  • prostatectomy
  • robotic surgery

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy : A step-by-step guide to exposure and efficiency. / Williams, Stephen; Bozkurt, Yasar; Achim, Mary; Achim, Grace; Davis, John W.

In: BJU International, Vol. 117, No. 1, 01.01.2016, p. 192-198.

Research output: Contribution to journalArticle

@article{8b89046563754a2f8755ea02d6f7ef7d,
title = "Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy: A step-by-step guide to exposure and efficiency",
abstract = "Objective To describe a novel, step-by-step approach to robot-assisted extended pelvic lymph node dissection (ePLND) at the time of robot-assisted radical prostatectomy (RARP) for intermediate-high risk prostate cancer. Patient and Methods The sequence of ePLND is at the beginning of the operation to take advantage of greater visibility of the deeper hypogastric planes. The urachus is left intact for an exposure/retraction point. The anatomy is described in terms of lymph nodes (LNs) that are easily retrieved vs those that require additional manipulation of the anatomy, and a determined surgeon. A representative cohort of 167 RARPs was queried for representative metrics that distinguish the ePLND: 146 primary cases and 21 with neoadjuvant systemic therapy. Results The median (interquartile range, IQR) LN yield was 22 (16-28) for primary surgeries and 21 (16-23) for neoadjuvant cases. The percentage of cases with positive LNs (pN1) was 16.4{\%} for primary and 29{\%} for neoadjuvant. The hypogastric LNs were involved in 75{\%} of pN1 primary cases and uniquely positive in 33{\%}. Each side of ePLND took the attending surgeon a median (IQR) of 16 (13-20) min and trainees 25 (24-38) min. Conclusions Robot-assisted ePLND before RARP provides an anatomical approach to surgical extirpation mimicking the open approach. We think this sequence offers efficiency and efficacy advantages in high-risk and select intermediate-risk patients with prostate cancer undergoing RARP.",
keywords = "high risk, lymphadenectomy, prostate cancer, prostatectomy, robotic surgery",
author = "Stephen Williams and Yasar Bozkurt and Mary Achim and Grace Achim and Davis, {John W.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/bju.13228",
language = "English (US)",
volume = "117",
pages = "192--198",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy

T2 - A step-by-step guide to exposure and efficiency

AU - Williams, Stephen

AU - Bozkurt, Yasar

AU - Achim, Mary

AU - Achim, Grace

AU - Davis, John W.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective To describe a novel, step-by-step approach to robot-assisted extended pelvic lymph node dissection (ePLND) at the time of robot-assisted radical prostatectomy (RARP) for intermediate-high risk prostate cancer. Patient and Methods The sequence of ePLND is at the beginning of the operation to take advantage of greater visibility of the deeper hypogastric planes. The urachus is left intact for an exposure/retraction point. The anatomy is described in terms of lymph nodes (LNs) that are easily retrieved vs those that require additional manipulation of the anatomy, and a determined surgeon. A representative cohort of 167 RARPs was queried for representative metrics that distinguish the ePLND: 146 primary cases and 21 with neoadjuvant systemic therapy. Results The median (interquartile range, IQR) LN yield was 22 (16-28) for primary surgeries and 21 (16-23) for neoadjuvant cases. The percentage of cases with positive LNs (pN1) was 16.4% for primary and 29% for neoadjuvant. The hypogastric LNs were involved in 75% of pN1 primary cases and uniquely positive in 33%. Each side of ePLND took the attending surgeon a median (IQR) of 16 (13-20) min and trainees 25 (24-38) min. Conclusions Robot-assisted ePLND before RARP provides an anatomical approach to surgical extirpation mimicking the open approach. We think this sequence offers efficiency and efficacy advantages in high-risk and select intermediate-risk patients with prostate cancer undergoing RARP.

AB - Objective To describe a novel, step-by-step approach to robot-assisted extended pelvic lymph node dissection (ePLND) at the time of robot-assisted radical prostatectomy (RARP) for intermediate-high risk prostate cancer. Patient and Methods The sequence of ePLND is at the beginning of the operation to take advantage of greater visibility of the deeper hypogastric planes. The urachus is left intact for an exposure/retraction point. The anatomy is described in terms of lymph nodes (LNs) that are easily retrieved vs those that require additional manipulation of the anatomy, and a determined surgeon. A representative cohort of 167 RARPs was queried for representative metrics that distinguish the ePLND: 146 primary cases and 21 with neoadjuvant systemic therapy. Results The median (interquartile range, IQR) LN yield was 22 (16-28) for primary surgeries and 21 (16-23) for neoadjuvant cases. The percentage of cases with positive LNs (pN1) was 16.4% for primary and 29% for neoadjuvant. The hypogastric LNs were involved in 75% of pN1 primary cases and uniquely positive in 33%. Each side of ePLND took the attending surgeon a median (IQR) of 16 (13-20) min and trainees 25 (24-38) min. Conclusions Robot-assisted ePLND before RARP provides an anatomical approach to surgical extirpation mimicking the open approach. We think this sequence offers efficiency and efficacy advantages in high-risk and select intermediate-risk patients with prostate cancer undergoing RARP.

KW - high risk

KW - lymphadenectomy

KW - prostate cancer

KW - prostatectomy

KW - robotic surgery

UR - http://www.scopus.com/inward/record.url?scp=84951567898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951567898&partnerID=8YFLogxK

U2 - 10.1111/bju.13228

DO - 10.1111/bju.13228

M3 - Article

VL - 117

SP - 192

EP - 198

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -